

Silvio Garattini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2410079/silvio-garattini-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

277 papers	8,856 citations	48 h-index	84 g-index
308 ext. papers	9,838 ext. citations	10.1 avg, IF	5.79 L-index

#	Paper	IF	Citations
277	Brain Kynurenine Pathway and Functional Outcome of Rats Resuscitated From Cardiac Arrest. <i>Journal of the American Heart Association</i> , 2021 , 10, e021071	6	
276	Quality, efficacy, safety-it is not enough!. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 1425-1426	6.8	1
275	Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies. <i>Frontiers in Pharmacology</i> , 2021 , 12, 685604	5.6	1
274	Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients sera. <i>Scientific Reports</i> , 2021 , 11, 14976	4.9	2
273	We are more than our omics. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 1043-1044	2.8	1
272	Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 170-174	3.8	6
271	Clinical evidence supporting the marketing authorization of biosimilars in Europe. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 557-566	2.8	5
270	Italian controlled trials to assess prevention and treatment of malaria, 1900-1930s. <i>Journal of the Royal Society of Medicine</i> , 2019 , 112, 349-353	2.3	2
269	Embedding patient- and public health-oriented research in a national health service: the GISSI experience. <i>Journal of the Royal Society of Medicine</i> , 2019 , 112, 200-204	2.3	2
268	New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. <i>Journal of Clinical and Experimental Hepatology</i> , 2019 , 9, 522-538	4.1	22
267	Looking for safety but overlooking efficacy: Non-inferiority trials of anti-diabetics. <i>European Journal of Internal Medicine</i> , 2019 , 67, e9-e10	3.9	
266	A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. <i>Scientific Reports</i> , 2019 , 9, 2064	4.9	32
265	Cannabis as a medicine. An update of the Italian reality. <i>European Journal of Internal Medicine</i> , 2019 , 60, e9-e10	3.9	3
264	Peripheral arterial disease: Changes in clinical outcomes and therapeutic strategies in two cohorts, from 2002 to 2008 and from 2008 to 2014. A population-based study. <i>European Journal of Preventive Cardiology</i> , 2018 , 25, 1735-1743	3.9	7
263	Preapproval and postapproval evidence on drugs for multiple sclerosis. <i>Neurology</i> , 2018 , 90, 964-973	6.5	11
262	Outrageous prices of orphan drugs: a call for collaboration. <i>Lancet, The</i> , 2018 , 392, 791-794	40	69
261	Myth #6: Health Care Is Rightly Controlled by the Public Sector, for the Sake of Equality 2018 , 155-176		

260	Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 373-375	2.8	2
259	Funding is not enough. <i>European Journal of Internal Medicine</i> , 2018 , 57, e8	3.9	
258	A disease looking for innovative drugs: The case of pulmonary arterial hypertension. <i>European Journal of Internal Medicine</i> , 2018 , 55, 47-51	3.9	3
257	A meritorious move against homeopathy. <i>European Journal of Internal Medicine</i> , 2018 , 55, e16	3.9	1
256	Ethics of reviewing scientific publications. <i>European Journal of Internal Medicine</i> , 2017 , 40, 22-25	3.9	6
255	Can systematic reviews contribute to regulatory decisions?. <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 507-509	2.8	6
254	Animal testing is still the best way to find new treatments for patients. <i>European Journal of Internal Medicine</i> , 2017 , 39, 32-35	3.9	25
253	Barriers to the conduct of randomised clinical trials within all disease areas. <i>Trials</i> , 2017 , 18, 360	2.8	45
252	Evidence-based practice within nutrition: what are the barriers for improving the evidence and how can they be dealt with?. <i>Trials</i> , 2017 , 18, 425	2.8	14
251	Specific barriers to the conduct of randomised clinical trials on medical devices. <i>Trials</i> , 2017 , 18, 427	2.8	39
250	A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?. <i>Trials</i> , 2017 , 18, 556	2.8	34
249	Helping ethics committees separate the wheat from the chaff. <i>European Journal of Internal Medicine</i> , 2017 , 44, e15	3.9	
248	Marketing masked as clinical research. The Phase IIIB studies and other sample cases. <i>European Journal of Internal Medicine</i> , 2017 , 44, e16-e17	3.9	
247	Clinical research on rare diseases of children: neuroblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 267-273	3.5	2
246	General Practitioners and Dentists: A Call for Action Against Tobacco. <i>Nicotine and Tobacco Research</i> , 2016 , 18, 2202-2208	4.9	5
245	Older patients are still under-represented in clinical trials of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 32	9	29
244	Trials, Regulation and tribulations. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 503-5	2.8	5
243	A European multi-language initiative to make the general population aware of independent clinical research: the European Communication on Research Awareness Need project. <i>Trials</i> , 2016 , 17, 19	2.8	9

242	Letting post-marketing bridge the evidence gap: the case of orphan drugs. <i>BMJ, The</i> , 2016 , 353, i2978	5.9	31
241	Psychiatric Pharmacotherapy in Coronary Artery Disease Patients 2016 , 121-130		
240	Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement. <i>Journal of Market Access & Health Policy</i> , 2016 , 4,	3.7	11
239	The European Medicines Agency is still too close to industry. <i>BMJ, The</i> , 2016 , 353, i2412	5.9	7
238	Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them. <i>European Journal of Internal Medicine</i> , 2016 , 32, 13-21	3.9	69
237	Health care: Make pharma justify the price of drugs. <i>Nature</i> , 2015 , 523, 290	50.4	3
236	The contradictions of homeopathy legislation. <i>European Journal of Internal Medicine</i> , 2015 , 26, 230-1	3.9	1
235	Rare diseases and effective treatments: are we delivering?. <i>Lancet, The</i> , 2015 , 385, 750-2	40	32
234	Approvals of drugs with uncertain benefit-risk profiles in Europe. <i>European Journal of Internal Medicine</i> , 2015 , 26, 572-84	3.9	63
233	More on homeopathy. <i>European Journal of Internal Medicine</i> , 2015 , 26, e20	3.9	
232	Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. <i>Cochrane Database of Systematic Reviews</i> , 2014 , CD011230		79
231	Most appropriate animal models to study the efficacy of statins: a systematic review. <i>European Journal of Clinical Investigation</i> , 2014 , 44, 848-71	4.6	23
230	Drug development: how academia, industry and authorities interact. <i>Nature Reviews Nephrology</i> , 2014 , 10, 602-10	14.9	3
229	Homeopathy cannot even be used to replace placebo. <i>European Journal of Internal Medicine</i> , 2014 , 25, e68	3.9	1
228	The pharmacological point of view of resistance to therapy in tumors. <i>Cancer Treatment Reviews</i> , 2014 , 40, 909-16	14.4	32
227	Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration 2014 ,		18
226	Stamina therapies: Time to call a halt. <i>Nature</i> , 2014 , 506, 434	50.4	2
225	Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. <i>Journal of Comparative Effectiveness Research</i> , 2014 , 3, 399-422	2.1	38

224	Fostering EMA's transparency policy. <i>European Journal of Internal Medicine</i> , 2014 , 25, 681-4	3.9	7
223	Flaws in animal studies exploring statins and impact on meta-analysis. <i>European Journal of Clinical Investigation</i> , 2014 , 44, 597-612	4.6	18
222	EMA's transparency seems to be opaque. <i>Lancet, The</i> , 2014 , 384, 1847	4.0	5
221	E-cigarette awareness, use, and harm perceptions in Italy: a national representative survey. <i>Nicotine and Tobacco Research</i> , 2014 , 16, 1541-8	4.9	60
220	How to increase value and reduce waste when research priorities are set. <i>Lancet, The</i> , 2014 , 383, 156-65	4.0	826
219	Clinical trial registries: from an omen to a common and disclosed practice. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 1725-6	2.8	3
218	Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 1009-24	2.8	77
217	Placebo? no thanks, it might be bad for me!. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 711-4	2.8	17
216	Reconsidering the Declaration of Helsinki. <i>Lancet, The</i> , 2013 , 382, 1247	4.0	5
215	The European Commission should require better medicines, not just faster reimbursements. <i>European Journal of Internal Medicine</i> , 2013 , 24, e1	3.9	2
214	A failed attempt at collaboration. <i>BMJ, The</i> , 2013 , 347, f5354	5.9	7
213	Solicited self-referencing undermines the credibility of researchers and journals. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 481-2	15.4	1
212	Effects of physical inactivity on non-communicable diseases. <i>Lancet, The</i> , 2012 , 380, 1553; author reply 1553-4	4.0	8
211	Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey. <i>PLoS ONE</i> , 2012 , 7, e34974	3.7	23
210	EMA's reflection on placebo does not reflect patients' interests. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 877-9	2.8	11
209	Laparoscopic approach to acute abdomen from the Consensus Development Conference of the Società Italiana di Chirurgia Endoscopica e nuove tecnologie (SICE), Associazione Chirurghi Ospedalieri Italiani (ACOI), Società Italiana di Chirurgia (SIC), Società Italiana di Chirurgia d'Urgenza e del Trauma (SICUT), Società Italiana di Chirurgia nell'Ospedale Privato (SICOP), and the European Association for Endoscopic Surgery (EAES). <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012 , 26, 2134-64	5.2	150
208	Informed consent: meet patients' needs. <i>Nature</i> , 2012 , 483, 36	50.4	
207	Pre-market clinical evaluations of innovative high-risk medical devices in Europe. <i>International Journal of Technology Assessment in Health Care</i> , 2012 , 28, 278-84	1.8	31

206	Antibiotics versus surgery for appendicitis. <i>Lancet, The</i> , 2011 , 378, 1067-8; author reply 1068	4.0	1
205	Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. <i>Journal of Comorbidity</i> , 2011 , 1, 28-44	4	132
204	Alternative medical practices: flashbacks from the Dark Ages. <i>European Journal of Internal Medicine</i> , 2010 , 21, 245-6	3.9	2
203	Evaluation of benefit-risk. <i>Pharmacoeconomics</i> , 2010 , 28, 981-6	4.4	10
202	Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. <i>BMC Health Services Research</i> , 2010 , 10, 153	2.9	147
201	Europe@ opportunity to open up drug regulation. <i>BMJ, The</i> , 2010 , 340, c1578	5.9	7
200	Bevacizumab and ranibizumab. A matter of public interest. <i>BMJ, The</i> , 2010 , 341, c3721	5.9	2
199	Rosiglitazone and the need for a new drug safety agency. <i>BMJ, The</i> , 2010 , 341, c5506	5.9	4
198	Limits of add-on trials: antirheumatic drugs. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 33-41	2.8	7
197	Ethics in clinical research. <i>Journal of Hepatology</i> , 2009 , 51, 792-7	13.4	20
196	Predicting the clinical relevance of drug interactions from pre-approval studies. <i>Drug Safety</i> , 2009 , 32, 1017-39	5.1	14
195	Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. <i>Lancet Infectious Diseases, The</i> , 2009 , 9, 67-72	25.5	19
194	Exenatide for type 2 diabetes. <i>Lancet, The</i> , 2009 , 373, 122; author reply 122-3	4.0	
193	Homoeopathy: not a matter for drug-regulatory authorities. <i>Lancet, The</i> , 2009 , 374, 1578-80	4.0	10
192	Patients and the public deserve big changes in evaluation of drugs. <i>BMJ, The</i> , 2009 , 338, b1025	5.9	44
191	Italy must invest more in science and technology. <i>Nature</i> , 2008 , 452, 685	50.4	2
190	Thrombolysis or nothing for acute myocardial infarction? It's all the same!. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 955-8	3.8	2
189	Provision of information on regulatory authorities' websites. <i>Internal Medicine Journal</i> , 2008 , 38, 559-67	1.6	11

188	The ethics of non-inferiority trials [AuthorsReply. <i>Lancet, The</i> , 2008 , 371, 896-897	4.0	6
187	Rare diseases: what's next?. <i>Lancet, The</i> , 2008 , 371, 1978-9	4.0	26
186	Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. <i>Pharmacoeconomics</i> , 2008 , 26, 91-8	4.4	39
185	Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. <i>Pharmacoeconomics</i> , 2008 , 26, 537-50	4.4	61
184	Do we learn the right things from clinical trials?. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 115-25	2.8	2
183	Efficacy and safety of immunosuppressive drugs approved in EU through the centralised procedure. <i>European Journal of Clinical Pharmacology</i> , 2007 , 63, 707-12	2.8	2
182	Haematological anticancer drugs in Europe: any added value at the time of approval?. <i>European Journal of Clinical Pharmacology</i> , 2007 , 63, 713-9	2.8	15
181	New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval. <i>European Journal of Clinical Pharmacology</i> , 2007 , 63, 879-89	2.8	12
180	CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation?. <i>Psychopharmacology</i> , 2007 , 190, 265-8	4.7	7
179	A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. <i>Archives of Internal Medicine</i> , 2007 , 167, 1791-7		27
178	Long-chain n-3 fatty acids in lipid rafts: implications for anti-inflammatory effects. <i>Journal of Cardiovascular Medicine</i> , 2007 , 8 Suppl 1, S30-3	1.9	7
177	How can we regulate medicines better?. <i>BMJ, The</i> , 2007 , 335, 803-5	5.9	35
176	Smoking in Italy 2005-2006: effects of a comprehensive National Tobacco Regulation. <i>Preventive Medicine</i> , 2007 , 45, 198-201	4.3	73
175	Pharmacokinetics in cancer chemotherapy. <i>European Journal of Cancer</i> , 2007 , 43, 271-82	7.5	21
174	Non-inferiority trials are unethical because they disregard patients' interests. <i>Lancet, The</i> , 2007 , 370, 1875-7	4.0	151
173	Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. <i>International Clinical Psychopharmacology</i> , 2006 , 21, 319-36	2.2	71
172	Mild depression in general practice: is the automatism of antidepressant prescribing an evidence-based approach?. <i>Acta Psychiatrica Scandinavica</i> , 2006 , 113, 449-51	6.5	7
171	Orphan drug development is progressing too slowly. <i>British Journal of Clinical Pharmacology</i> , 2006 , 61, 355-60	3.8	48

170	Disappointing biotech. <i>BMJ, The</i> , 2005 , 331, 895-7	5.9	39
169	Discontinuation of Vioxx. <i>Lancet, The</i> , 2005 , 365, 24	4.0	1
168	Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. <i>British Journal of Cancer</i> , 2005 , 93, 504-9	8.7	67
167	Designing the most favourable study design. <i>European Journal of Clinical Pharmacology</i> , 2005 , 61, 85-6	2.8	1
166	The impact of European regulatory policies on psychotropic drug prescribing patterns. <i>International Review of Psychiatry</i> , 2005 , 17, 199-204	3.6	5
165	Use of cigarette vending machines by minors in Italy. <i>International Journal of Epidemiology</i> , 2004 , 33, 432	7.8	2
164	Risk:benefit assessment of old medicines. <i>British Journal of Clinical Pharmacology</i> , 2004 , 58, 581-6	3.8	5
163	Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004 , 28, 819-27	5.5	81
162	Independent clinical research in Europe. <i>Lancet, The</i> , 2004 , 364, 1723-6	4.0	17
161	The cultural shift in Italy's pharmaceutical policy in 1994: a case history. <i>Journal of Ambulatory Care Management</i> , 2004 , 27, 120-6	0.8	4
160	A critique to the European regulatory system. <i>Journal of Ambulatory Care Management</i> , 2004 , 27, 98-104	0.8	4
159	How can research ethics committees protect patients better?. <i>BMJ, The</i> , 2003 , 326, 1199-201	5.9	24
158	European regulatory policies on medicines and public health needs. <i>European Journal of Public Health</i> , 2003 , 13, 246-51	2.1	10
157	Varying and "atypical" indications for atypical antipsychotics. <i>Psychopharmacology</i> , 2003 , 169, 205-6	4.7	21
156	Efficacy, safety and cost of new drugs acting on the central nervous system. <i>European Journal of Clinical Pharmacology</i> , 2003 , 59, 79-84	2.8	7
155	Efficacy, safety and cost of new cardiovascular drugs: a survey. <i>European Journal of Clinical Pharmacology</i> , 2003 , 59, 701-6	2.8	10
154	Sparing animals and progressing in science. <i>Trends in Pharmacological Sciences</i> , 2003 , 24, 616-7	13.2	1
153	Light and shade in proposed revision of EU drug-regulatory legislation. <i>Lancet, The</i> , 2003 , 361, 635-6	4.0	10

152	Confidentiality. <i>Lancet, The</i> , 2003 , 362, 1078-9	4.0	3
151	European Council waters down European Parliament's drug-regulatory legislation. <i>Lancet, The</i> , 2003 , 362, 1688-9	4.0	2
150	Drug sales in four European countries still differ. <i>BMJ, The</i> , 2003 , 327, 1404-5	5.9	0
149	Clinical databases of patients receiving antidepressants. The missing link between research and practice?. <i>Journal of Affective Disorders</i> , 2002 , 70, 191-6	6.6	7
148	Fluoxetine dose and outcome in antidepressant drug trials. <i>European Journal of Clinical Pharmacology</i> , 2002 , 58, 379-86	2.8	18
147	Toward new legislation on drugs in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2002 , 2, 51-6	2.2	
146	Efficacy, safety, and cost of new anticancer drugs. <i>BMJ, The</i> , 2002 , 325, 269-71	5.9	71
145	Ethics of testing drugs with readily available alternatives. <i>Lancet, The</i> , 2002 , 360, 647	4.0	3
144	Antioxidant strategy for cardiovascular disease. <i>Lancet, The</i> , 2001 , 357, 1706	4.0	2
143	Adjusting Europe's drug regulation to public health needs. <i>Lancet, The</i> , 2001 , 358, 64-7	4.0	51
142	Attitudes towards smoking regulation in Italy. <i>Lancet, The</i> , 2001 , 358, 245	4.0	16
141	Modulating the profit motive to meet needs of the less-developed world. <i>Lancet, The</i> , 2001 , 358, 1638-41	4.0	16
140	Health-related quality of life (HR-QOL) and regulatory issues. An assessment of the European Agency for the Evaluation of Medicinal Products (EMA) recommendations on the use of HR-QOL measures in drug approval. <i>Pharmacoeconomics</i> , 2001 , 19, 187-95	4.4	66
139	New approach to clinical trials and drug registration. Author's suggestions for drug approval are questionable. <i>BMJ: British Medical Journal</i> , 2001 , 323, 341		3
138	Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. <i>European Journal of Neuroscience</i> , 2000 , 12, 2623-33	3.5	378
137	Policing the European pharmaceutical market's priorities. <i>European Journal of Clinical Pharmacology</i> , 2000 , 56, 441-3	2.8	2
136	Nomograms used to define the short-term treatment with PGE(1) in patients with intermittent claudication and critical ischemia. The ORACLE (Occlusion Revascularization in the Atherosclerotic Critical Limb) Study Group. The European Study. <i>Angiology</i> , 2000 , 51, S3-13; discussion S14	2.1	4
135	Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic Critical Leg Ischaemia Group. <i>European Journal of Vascular and Endovascular Surgery</i> , 1999 , 18, 401-10	2.3	98

134	Multicentre clinical trials. <i>Lancet, The</i> , 1999 , 353, 930	40	2
133	"Pharmacocentricity": from elixirs to magic bullets. <i>Lancet, The</i> , 1999 , 354 Suppl, SIV51	40	0
132	Inconclusive messages from equivalence trials in thrombolysis. <i>Heart</i> , 1999 , 81, 675-6	5.1	8
131	How to improve medical information on drugs. <i>Lancet, The</i> , 1998 , 352, 151-2	40	5
130	The drug market in four European countries. <i>Pharmacoeconomics</i> , 1998 , 14 Suppl 1, 69-79	4.4	3
129	Discrepancy remains in pharmaceutical prescriptions in four European countries. <i>BMJ: British Medical Journal</i> , 1998 , 317, 947		2
128	Drug metabolism: from experiments to regulatory aspects. <i>Drug Metabolism Reviews</i> , 1997 , 29, 853-86	7	3
127	Tryptophan and depression. <i>Lancet, The</i> , 1997 , 349, 1553-4	40	3
126	Health inequalities in Italy. Collaborative Group of the Primary Prevention Project. <i>Lancet, The</i> , 1997 , 350, 1557-8	40	
125	Mechanism of inhibition of tumor necrosis factor production by chlorpromazine and its derivatives in mice. <i>European Journal of Pharmacology</i> , 1996 , 317, 369-76	5.3	14
124	A prospective epidemiological survey of the natural history of chronic critical leg ischaemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 1996 , 11, 112-120	2.3	22
123	In vitro and in vivo effects of the anorectic agent dexfenfluramine on the central serotonergic neuronal systems of non-human primates. A comparison with the rat. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1996 , 353, 641-7	3.4	18
122	Biological actions of drugs affecting serotonin and eating. <i>Obesity</i> , 1995 , 3 Suppl 4, 463S-470S		31
121	Cultural shift in Italy's drug policy. <i>Lancet, The</i> , 1995 , 346, 5-6	40	27
120	Pharmaceutical prescriptions in Italy. <i>International Journal of Technology Assessment in Health Care</i> , 1995 , 11, 417-27	1.8	3
119	Perspectives in the field of drug metabolism. <i>Drug Metabolism Reviews</i> , 1994 , 26, 537-73	7	2
118	A comparative analysis of the pharmaceutical market in four European countries. <i>Pharmacoeconomics</i> , 1994 , 6, 417-23	4.4	10
117	Treatment of idiopathic membranous glomerulopathy. <i>Current Opinion in Nephrology and Hypertension</i> , 1994 , 3, 155-63	3.5	6

116	Acute noise stress reduces [3H]5-hydroxytryptamine uptake in rat brain synaptosomes: protective effects of buspirone and tianeptine. <i>European Journal of Pharmacology</i> , 1993 , 241, 255-60	5.3	23
115	The role of d-norfenfluramine in the indole-depleting effect of d-fenfluramine in the rat. <i>European Journal of Pharmacology</i> , 1993 , 233, 71-7	5.3	29
114	The effects of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain. <i>British Journal of Pharmacology</i> , 1993 , 110, 355-9	8.6	37
113	Drug utilisation review and pharmacoeconomics: interaction after parallel development?. <i>Pharmacoeconomics</i> , 1993 , 4, 162-72	4.4	9
112	Narcotic drug use for severe pain. <i>Lancet, The</i> , 1993 , 341, 1061-2	4.0	2
111	Illiteracy and maternal health: educate or die. <i>Lancet, The</i> , 1993 , 341, 1063-4	4.0	14
110	Prognosis of untreated patients with idiopathic membranous nephropathy. <i>New England Journal of Medicine</i> , 1993 , 329, 85-9	59.2	284
109	Neurochemical mechanism of action of anorectic drugs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1993 , 73, 63-8		87
108	Anorectic effect and brain concentrations of D-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on serotonergic mechanisms. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1993 , 347, 306-12	3.4	16
107	Preliminary survey on 2,3,7,8-TCDD in cellulose-containing consumer products on the Italian market. <i>Chemosphere</i> , 1993 , 27, 1561-1564	8.4	1
106	Pharmacology of second messengers: a critical appraisal. <i>Drug Metabolism Reviews</i> , 1992 , 24, 125-94	7	2
105	Feeding pattern studies suggest that d-fenfluramine and sertraline specifically enhance the state of satiety in rats. <i>European Journal of Pharmacology</i> , 1992 , 211, 137-42	5.3	16
104	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. <i>Kidney International</i> , 1992 , 42, 981-90	9.9	17
103	Releasing activities of d-fenfluramine and fluoxetine on rat hippocampal synaptosomes preloaded with [3H]serotonin. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1992 , 345, 1-6	3.4	49
102	Comparative studies on the anorectic activity of d-fenfluramine in mice, rats, and guinea pigs. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1991 , 343, 483-90	3.4	67
101	Role of 5-HT receptors in the effect of d-fenfluramine on gastric emptying and feeding behaviour as examined in the runway test. <i>European Journal of Pharmacology</i> , 1991 , 197, 69-73	5.3	8
100	Oral zeranol shortens the prolonged bleeding time of uremic rats. <i>Kidney International</i> , 1990 , 38, 96-100	9.9	5
99	The case of GISSI in changing the attitudes and practice of Italian cardiologists. <i>Statistics in Medicine</i> , 1990 , 9, 17-26; discussion 26-7	2.3	22

98	Formation of active metabolites of psychotropic drugs. An updated review of their significance. <i>Clinical Pharmacokinetics</i> , 1990 , 18, 434-59	6.2	49
97	Effect of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine on hippocampal serotonergic system, studied in freely moving rats. <i>Life Sciences</i> , 1990 , 46, 197-205	6.8	6
96	Significance of Fenfluramine Neurotoxicity: A Kinetic Approach 1990 , 637-643		
95	Animal use at a Milan research institute. <i>Lancet, The</i> , 1989 , 2, 1106	4.0	2
94	Serotonin and the pharmacology of eating disorders. <i>Annals of the New York Academy of Sciences</i> , 1989 , 575, 194-207; discussion 207-8	6.5	25
93	Antiinflammatory action of salicylates: aspirin is not a prodrug for salicylate against rat carrageenin pleurisy. <i>European Journal of Pharmacology</i> , 1989 , 159, 257-64	5.3	13
92	Effect of L-cysteine on the long-term depletion of brain indoles caused by p-chloroamphetamine and d-fenfluramine in rats. Relation to brain drug concentrations. <i>European Journal of Pharmacology</i> , 1989 , 163, 77-83	5.3	22
91	Effects of the l isomer of fenfluramine on dopamine mechanisms in rat brain: further studies. <i>European Journal of Pharmacology</i> , 1989 , 164, 241-8	5.3	22
90	Pharmacology of amineptine: synthesis and updating. <i>Clinical Neuropharmacology</i> , 1989 , 12 Suppl 2, S13-84	4.4	16
89	Catecholamine receptor binding in rat kidney: effect of aging. <i>Kidney International</i> , 1988 , 33, 1073-7	9.9	26
88	Blockade of alpha 2-adrenoceptors by 1-(2-pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspirone. <i>European Journal of Pharmacology</i> , 1988 , 147, 343-50	5.3	51
87	The alpha 2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP). <i>European Journal of Pharmacology</i> , 1988 , 151, 365-71	5.3	61
86	Different effects of fenfluramine isomers and metabolites on extracellular 5-HIAA in nucleus accumbens and hippocampus of freely moving rats. <i>European Journal of Pharmacology</i> , 1988 , 153, 295-9	5.3	26
85	Remedies for tropical diseases. <i>Lancet, The</i> , 1988 , 1, 1338	4.0	2
84	Disposition of D-fenfluramine in lean and obese rats. <i>Appetite</i> , 1988 , 10, 45-55	4.5	12
83	Biochemical hypotheses on antidepressant drugs: a guide for clinicians or a toy for pharmacologists?. <i>Psychological Medicine</i> , 1988 , 18, 287-304	6.9	40
82	The need to compare the effectiveness of the available antidepressant drugs. <i>British Journal of Psychiatry</i> , 1988 , 152, 140-1	5.4	2
81	Defective Fibrinolytic Response in Atherosclerotic Patients [Effect of Iloprost and Its Possible Mechanism of Action. <i>Thrombosis and Haemostasis</i> , 1988 , 60, 141-144	7	18

80	From fenfluramine racemate to d-fenfluramine. Specificity and potency of the effects on the serotonergic system and food intake. <i>Annals of the New York Academy of Sciences</i> , 1987 , 499, 156-66	6.5	104
79	What is the basis for the use of steroids in the treatment of idiopathic membranous nephropathy?. <i>Nephron</i> , 1987 , 45, 1-6	3.3	9
78	Effects of chlorinated organics on intermediates in the heme pathway and on uroporphyrinogen decarboxylase. <i>Annals of the New York Academy of Sciences</i> , 1987 , 514, 128-40	6.5	7
77	ItalyATTITUDES TO LEGISLATION ON RESTRICTION OF SMOKING. <i>Lancet, The</i> , 1987 , 329, 1310	4.0	8
76	Response of human platelets exposed to arachidonate upon stimulation with other agonists: possible role of Ca ²⁺ movement. <i>Biochemical and Biophysical Research Communications</i> , 1987 , 149, 1193-9	3.4	5
75	Effect of etidronate disodium on the interactions between malignancy and bone. <i>American Journal of Medicine</i> , 1987 , 82, 29-33	2.4	100
74	Perspectives in the treatment of cancer metastasis. <i>Clinical and Experimental Metastasis</i> , 1987 , 5, 105-24	4.7	3
73	Reduction of beta-adrenergic receptors by tertatolol: an additional mechanism for beta-adrenergic blockade. <i>Clinical Pharmacology and Therapeutics</i> , 1986 , 39, 245-54	6.1	21
72	1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. <i>Pharmacology</i> , 1986 , 33, 46-51	2.3	108
71	Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. <i>New England Journal of Medicine</i> , 1986 , 314, 1402-6	59.2	448
70	Disposition of apomorphine in rat brain areas: relationship to stereotypy. <i>European Journal of Pharmacology</i> , 1986 , 131, 229-36	5.3	28
69	d- and l-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat. <i>European Journal of Pharmacology</i> , 1986 , 120, 9-15	5.3	122
68	Anorectic effect of fenfluramine isomers and metabolites: relationship between brain levels and in vitro potencies on serotonergic mechanisms. <i>Psychopharmacology</i> , 1985 , 85, 111-4	4.7	87
67	Toxic effects of chemicals: difficulties in extrapolating data from animals to man. <i>CRC Critical Reviews in Toxicology</i> , 1985 , 16, 1-29		37
66	Active drug metabolites. An overview of their relevance in clinical pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1985 , 10, 216-27	6.2	26
65	Blockade of the diazepam-induced increase in rat striatal acetylcholine content by the specific benzodiazepine antagonists ethyl-beta-carboline-3-carboxylate and Ro 15-1788. <i>Brain Research</i> , 1985 , 336, 342-5	3.7	10
64	Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors. <i>Biochemical Pharmacology</i> , 1985 , 34, 307-10	6	11
63	Inhibition of human platelet thromboxane generation by aspirin in the absence of measurable drug levels in peripheral blood. <i>Biochemical Pharmacology</i> , 1985 , 34, 1839-41	6	19

62	In vivo stereospecific [³ H]spiperone binding in rat brain: characteristics, regional distribution, kinetics and pharmacological properties. <i>European Journal of Pharmacology</i> , 1985 , 116, 63-74	5.3	23
61	Brain Receptor Occupation and Kinetics of Benzodiazepine Action 1985 , 537-543		1
60	Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective. <i>Agents and Actions</i> , 1984 , 14, 109-12		5
59	Diazepam increases membrane fluidity of rat hippocampus synaptosomes. <i>FEBS Letters</i> , 1984 , 173, 255-8.	5.8	26
58	Drugs: guide and caveats to explanatory and descriptive approaches--I. A critical evaluation of the current status of antidepressant drugs. <i>Journal of Psychiatric Research</i> , 1984 , 18, 373-90	5.2	11
57	Anxiolytic activity on locus coeruleus-mediated suppression of muricidal aggression. <i>European Journal of Pharmacology</i> , 1984 , 105, 323-6	5.3	30
56	Central side effects of pentamethylmelamine: biochemical and behavioural studies. <i>Biochemical Pharmacology</i> , 1984 , 33, 4011-5	6	1
55	SQ 22536, an Adenylate-Cyclase Inhibitor, Prevents the Antiplatelet Effect of Dazoxiben, a Thromboxane-Synthetase Inhibitor. <i>Thrombosis and Haemostasis</i> , 1984 , 51, 125-128	7	15
54	Plasma pyroglutamic acid levels after oral administration of monosodium glutamate to human volunteers. <i>Toxicology Letters</i> , 1983 , 15, 123-9	4.4	9
53	Lack of interaction of heparin with ADP and prostacyclin on rat platelets. <i>Thrombosis Research</i> , 1983 , 31, 397-400	8.2	4
52	Notes on xenobiotic metabolism. <i>Annals of the New York Academy of Sciences</i> , 1983 , 407, 1-25	6.5	13
51	Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma". <i>Science</i> , 1983 , 220, 517-9	33.3	45
50	Importance of establishing the presence of drug active metabolites. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1983 , 8, 97-108	2.7	7
49	Immunosuppressive effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin in strains of mice with different susceptibility to induction of aryl hydrocarbon hydroxylase. <i>Toxicology and Applied Pharmacology</i> , 1983 , 68, 434-41	4.6	123
48	Walker carcinoma 256: a model for studies on tumor-induced anorexia and cachexia. <i>Oncology</i> , 1982 , 39, 173-8	3.6	43
47	TCDD toxicology with particular reference to Seveso: introductory remarks. <i>Drug Metabolism Reviews</i> , 1982 , 13, 345-53	7	3
46	Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link. <i>Lancet, The</i> , 1982 , 2, 974-7	40	46
45	Aspirin inhibits platelet aggregation but not because it prevents thromboxane synthesis. <i>Lancet, The</i> , 1982 , 2, 775	40	6

44	Arachidonic acid induces human platelet-fibrin retraction: the role of platelet cyclic endoperoxides. <i>Thrombosis Research</i> , 1982 , 25, 299-306	8.2	2
43	Benzodiazepine receptors correlation with pharmacological responses in living animals. <i>Life Sciences</i> , 1982 , 31, 2025-35	6.8	48
42	Caffeine disposition after oral doses. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 32, 98-106	6.1	271
41	Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. <i>European Journal of Pharmacology</i> , 1982 , 85, 331-3	5.3	30
40	Thromboxane Synthetase Inhibition Results in Increased Platelet Sensitivity to Prostacyclin. <i>Thrombosis and Haemostasis</i> , 1982 , 47, 294-294	7	16
39	Evidence for covalent binding of adriamycin to rat liver microsomal proteins. <i>Biochemical Pharmacology</i> , 1981 , 30, 175-7	6	31
38	Effects of saccharin on primary humoral antibody production in rats. <i>Toxicology Letters</i> , 1981 , 8, 1-6	4.4	9
37	Central Mechanisms of Fenfluramine and Related Anorectic Drugs. <i>The Japanese Journal of Pharmacology</i> , 1981 , 31, 29-35		8
36	Characterization of tumor lines derived from spontaneous metastases of a transplanted murine sarcoma. <i>European Journal of Cancer</i> , 1981 , 17, 71-6		51
35	A murine ovarian tumor with unique metastasizing capacity. <i>European Journal of Cancer</i> , 1981 , 17, 651-8		18
34	Differential adriamycin distribution to blood components. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1981 , 6, 115-22	2.7	11
33	Divergent effects of macrophage toxins on growth of primary tumors and lung metastases in mice. <i>International Journal of Cancer</i> , 1980 , 25, 617-20	7.5	54
32	Influence of tumor on adriamycin concentration in blood cells. <i>Cancer Chemotherapy and Pharmacology</i> , 1980 , 4, 209-12	3.5	10
31	U-46619, a stable analogue of prostaglandin H ₂ , induces retraction of human platelet-rich plasma clots. <i>Thrombosis Research</i> , 1980 , 18, 543-5	8.2	7
30	Anorexia and cancer in animals and man. <i>Cancer Treatment Reviews</i> , 1980 , 7, 115-39	14.4	42
29	Evidence that it is possible to cause anorexia by increasing release and/or directly stimulating postsynaptic serotonin receptors in the brain. <i>Progress in Neuro-Psychopharmacology & Biological Psychiatry</i> , 1980 , 4, 363-9		48
28	In vitro effects of saccharin on cell-mediated host defence mechanisms. <i>Toxicology Letters</i> , 1980 , 5, 287-254	4.4	10
27	Increase in rat striatal acetylcholine content by d-fenfluramine, a serotonin releaser. <i>Life Sciences</i> , 1979 , 25, 1975-81	6.8	17

26	Macrophage-mediated cytostatic activity on tumour cells after treatment with Triton WR 1339. <i>European Journal of Cancer</i> , 1978 , 14, 229-35		0
25	The immunostimulatory activity of 3-(p-chlorophenyl)-2,3-dihydro-3-hydroxythiazole [3,2- α]-benzimidazole-2-acetic acid (NSC 208828). <i>European Journal of Cancer</i> , 1978 , 14, 393-400		7
24	Clinical pharmacokinetics of diazepam. <i>Clinical Pharmacokinetics</i> , 1978 , 3, 72-91	6.2	308
23	Distribution and localization of p-hydroxy-d-amphetamine in rat brain. <i>European Journal of Pharmacology</i> , 1978 , 52, 361-5	5.3	8
22	Different effects of methionine-enkephalin and (D-Ala ²)methionine-enkephalin amide on the metabolism of dopamine and norepinephrine in rat brain: fact or artifact?. <i>Brain Research</i> , 1978 , 146, 392-9	3.7	21
21	Effect of two non tricyclic antidepressant drugs on [¹⁴ C]5-hydroxytryptamine uptake by rat platelets. <i>Journal of Pharmacy and Pharmacology</i> , 1977 , 29, 546-9	4.8	11
20	The effect of methionine-enkephalin and D-alanine methionine-enkephalinamide on the concentration of dopamine metabolites in rat striatum. <i>European Journal of Pharmacology</i> , 1977 , 45, 207-9	5.3	22
19	Possible storage of (+)-amphetamine in catecholaminergic terminals of the striatum and brainstem. <i>European Journal of Pharmacology</i> , 1977 , 41, 275-9	5.3	11
18	Specificity of serotonergic involvement in the decrease of food intake induced by quipazine in the rat. <i>Life Sciences</i> , 1977 , 21, 1259-66	6.8	55
17	Effect of Phenobarbital on Cyclophosphamide Cytotoxic Activity and Pharmacokinetics in Mice. <i>Tumori</i> , 1977 , 63, 137-146	1.7	6
16	Effect of nomifensine on acetylcholine and choline in the rat striatum and brainstem. <i>European Journal of Pharmacology</i> , 1976 , 35, 199-201	5.3	6
15	Uptake of ¹⁴ C-5-hydroxytryptamine by human and rat platelets and its pharmacological inhibition. A comparative kinetic analysis. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1976 , 296, 59-65	3.4	47
14	Characterization of the immunostimulants levamisole and tetramisole. <i>European Journal of Cancer</i> , 1975 , 11, 555-63		53
13	The serotonergic system in the brain and its possible functional connections with other aminergic systems. <i>Life Sciences</i> , 1975 , 17, 1201-9	6.8	90
12	Effect of amphetamine and fenfluramine on brain noradrenaline and MOPEG-SO ₄ . <i>European Journal of Pharmacology</i> , 1975 , 34, 345-50	5.3	22
11	The effect of selective lesioning of brain catecholamine-containing neurons on the activity of various anorectics in the rat. <i>European Journal of Pharmacology</i> , 1975 , 34, 373-5	5.3	38
10	The effect of nomifensine on the depletion of brain serotonin and catecholamines induced respectively by fenfluramine and 6-hydroxydopamine in rats. <i>European Journal of Pharmacology</i> , 1975 , 34, 377-80	5.3	67
9	Notes on the Use of Gas-Liquid Chromatography Techniques for Determination of Psychotropic Drugs in Biological Samples 1975 , 25-61		

8	Biochemical aspects of the interaction between midbrain raphe and locus coeruleus in the rat. <i>Brain Research</i> , 1974 , 82, 178-82	3.7	118
7	Increase in striatal acetylcholine levels in vivo by piribedil a new dopamine receptor stimulant. <i>Life Sciences</i> , 1974 , 14, 1251-60	6.8	30
6	Effects of piribedil on noradrenaline and MOPEG-SO ₄ levels in the rat brain. <i>European Journal of Pharmacology</i> , 1974 , 28, 214-6	5.3	23
5	Effect of piribedil and one of its metabolites on the concentration of homovanillic acid in the rat brain. <i>European Journal of Pharmacology</i> , 1974 , 27, 245-8	5.3	18
4	Distribution of penfluridol in rats and mice. <i>European Journal of Pharmacology</i> , 1974 , 25, 291-5	5.3	11
3	Selective antimetastatic treatment--current status and future prospects. <i>Cancer Treatment Reviews</i> , 1974 , 1, 239-50	14.4	21
2	Effect of cyclophosphamide on the activity and distribution of pentobarbital in rats. <i>Biochemical Pharmacology</i> , 1973 , 22, 2609-14	6	7
1	Biliary excretion of conjugated hydroxyl benzodiazepines after administration of several benzodiazepines to rats, guinea pigs, and mice. <i>Journal of Pharmaceutical Sciences</i> , 1972 , 61, 965-6	3.9	19